throbber
John West
`Carol Tillis
`Eliane Sousa; Richard Chen; Christian Haudenschild
`Board slides from John West, ready to print
`Thursday, November 1, 2012 7:32:01 AM
`CEO Overview 16x9 1Nov2012 v2.pptx
`
`From:
`To:
`Cc:
`Subject:
`Date:
`Attachments:
`
`Hi Carol,
`
`I have 11 slides, attached.
`They are ready to print. Hopefully that's not a problem with the 16x9 format.
`
`Thanks,
`
`John
`
`Personalis EX2099
`
`

`

`CEO Overview
`
`John West
`
`Personalis, Inc. Board Meeting
`November 1, 2012
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`Personalis EX2099
`
`

`

`Agenda
`
`• Brief review of the company plan & where we are along it
`• Plans for commercial organization
`• Updates:
` Finance
` Expenditure approvals for recruitment & lab CapEx
` Operations
` Focus on early customers & pipeline
` R&D
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`2
`
`Personalis EX2099
`
`

`

`Key Intellectual Property & IP Potential Behind the Company
`
`• Licensed from Stanford:
`
`•
`
`IP Potential from Founders & Team:
`
` Databases (Source Lab) :
` PharmGKB
`(Russ Altman)
` VariMed
`(Atul Butte)
` MendelDB
`(Euan Ashley)
` Regulome
`(Mike Snyder)
`
` Patent Applications :
` Key accuracy IP - Improving allele
`choices in the human reference sequence
`
` Copyrights & Trademark :
` Aligned with the above
`
` Russ Altman - Pharmacogenomics
` Atul Butte
`- Complex diseases
` Euan Ashley - Mendelian diseases
` Mike Snyder - Gene regulation
`
`- Sequencing technology
`John West
`- Family sequencing
`- Sequencing accuracy
`
`
`
`
`
`
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`3
`
`Personalis EX2099
`
`

`

`Two Complementary Target Markets
`
`
`
`
`
`
`
`• Medical Research
`> 100k genomes / exomes / yr already
` Capacity growth: > 40% / year
`Total spending today on medically-
`related sequencing approx. $1B / year
`20-30% may be accessible with
`Personalis IP
` No regulatory or reimbursement barriers
`to market
`Technology needs refinement, validation
`& credibility from the research market,
`for clinical transition
`Build revenue & transition to profitability
`here first
`
`
`
`
`
`
`
`
`
`• Clinical Diagnostics
`Long-term, a much larger market
`> 2,000 tests routinely reimbursed now,
`based on prior generation DNA
`sequencing technology
` Mendelian disease applications normal
`Pharmacogenomics building acceptance
`Pathologists press to “own” this wave
` Regulatory, reimbursement and
`adoption hurdles for new tests
`Potential for future diagnostics is a
`major motivator for current research
`funding
`Start early but spend modestly by
`leveraging work already being done for
`the research market
`
`
`
`
`
`
`
`
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`4
`
`Personalis EX2099
`
`

`

`Business Model Choice to Commercialize Our IP
`
`• Bioinformatics
` Competing with culture of free
`exchange, government subsidized
` Can’t fully address the issues of
`data accuracy
` Outsourced data generation
`currently very slow (3-9 months !)
` Doesn’t fit accepted clinical
`diagnostics model
`
`• Lab assay + Analysis
` Specialty sample preps implement our
`IP & link to algorithms
` Fully address the issue of sequencing
`accuracy
` Combination may offer patent
`protection advantages
` Control turnaround time
` Challenges in CapEx, margins,
`utilization, obsolescence, scalability
` This is our primary choice, though we
`will work with just data if the customer
`already has it or we can’t realistically
`generate it (large # whole genomes)
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`5
`
`Personalis EX2099
`
`

`

`Service vs Product Business Model Choice
`Typical factors are technical complexity & lumpiness vs IP concern with outsourcing
`
`
`
`
`
`
`• Medical Research
`>60% of research sequencing is
`done by service organizations:
`Primarily internal core labs and
`Genome Centers
`Nominally non-profit
`Sometimes subsidized
` Next gen sequencing has sprouted
`service businesses in both
`sequencing and informatics
` Personalis initial research market
`offering is a service:
`
`From DNA to analysis
`
`• Clinical Diagnostics
` A centralized CLIA lab (service model)
`is the standard for “high-complexity”
`laboratory-developed clinical
`diagnostic tests (esp. genetics)
` CLIA is the only realistic regulatory
`path until sequencing instrument
`providers achieve FDA approval
` CLIA becoming a quality surrogate in
`research studies, esp pharma
` Personalis initial clinical strategy is a
`CLIA-lab diagnostic service:
`
`
`From blood sample to
`report
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`6
`
`Personalis EX2099
`
`

`

`Major steps planned in company development
`
`
`
`
`
`• Research Market business:
` Establish operations (Hiring, office & labs, establish processes)
`Initial service products: “data analysis” with / without standard sequencing
`1st revenue
`Initial service products with IP leveraged as a lab assay
` Additional analysis products
` Revenue ramp to profitability
`• Clinical Diagnostic business
` CLIA / CAP accredited lab established (vanilla capabilities – a foundation)
`Initial clinical products, disease-area focused
` Comprehensive genome interpretation as a long-term goal
`
`
`
`
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`7
`
`Personalis EX2099
`
`

`

`Personalis at 12 months
`1st non-CEO full-time employee started Nov 1, 2011
`
`
`
`
`
`• Research Market business:
` Establish operations (Hiring, office & labs, establish processes) Done
`Initial service products: “data analysis” with / without standard sequencing Beta
`1st revenue 2 customers, $870k, 1st “completion” by year-end
`Initial service products with IP leveraged as a lab assay In development
` Additional analysis products In development
` Revenue ramp to profitability 2013-2014
`• Clinical Diagnostic business
` CLIA / CAP accredited lab established (vanilla capabilities – a foundation) On track
`Initial clinical products, disease-area focused In definition
` Comprehensive genome interpretation as a long-term goal
`
`
`
`
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`8
`
`Personalis EX2099
`
`

`

`Personalis at 12 months
`1st non-CEO full-time employee started Nov 1, 2011
`
`Approx. 1/3 of Series A has
`been spent; Series B is in
`planning for H1 2013
`
`• Research Market business:
` Establish operations (Hiring, office & labs, establish processes) Done
`Initial service products: “data analysis” with / without standard sequencing Beta
`1st revenue 2 customers, $870k, 1st “completion” by year-end
`Initial service products with IP leveraged as a lab assay In development
` Additional analysis products In development
` Revenue ramp to profitability 2013-2014
`• Clinical Diagnostic business
` CLIA / CAP accredited lab established (vanilla capabilities – a foundation) On track
`Initial clinical products, disease-area focused In definition
` Comprehensive genome interpretation as a long-term goal
`
`
`
`
`
`
`
`
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`9
`
`Personalis EX2099
`
`

`

`Draft Commercial Organization
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`10
`
`Personalis EX2099
`
`

`

`Transition to Finance Update
`
`© Personalis Inc. All Rights Reserved. COMPANY CONFIDENTIAL.
`
`11
`
`Personalis EX2099
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket